Numascreen™ phage display libraries are first in market high-diversity libraries with over 1 billion for peptides > 20 aa. Using Numascreen we discover and optimize your high-affinity binders with unique properties.
Numatech™ serves as a unique high-titer expression platform enabling material supply in a short timeframe, at needed scales, reduced costs and the highest qualities. Evolved by nature, discovered by leading scientists, optimized and applied by Numaferm.
Numaferm is an ISO 9001:2015 certified company dedicated to quality and customer satisfaction. With a track record of over 200 successful peptide projects, Numaferm has become a trusted partner in the industry.
Sustainable and future-proof, Numatech reduces your carbon footprint and leaves out fine chemicals and organic solvents to meet higher safety standards.
Our lead discovery service identifies innovative, high-affine, highly-specific peptides against your target and makes use of proprietary Numascreen™ phage display libraries.
Developed by Eli Lilly, Teriparatide has become an important treatment for osteoporosis (Forsteo®). We designed a unique production process, outperforming everything on the market to make this treatment accessible, affordable and safe for every patient worldwide. Similar processes are available for other peptide APIs like PTH (1-84) and Liraglutide.
Together with RWTH Aachen, we developed a bifunctional adhesive-antimicrobial peptide to be used as a pesticide for agricultural applications. This peptide is highly active, rain-resistant, safe and does not pollute soil or food, making it superior to available alternatives.
In cooperation with Tunatech GmbH, various AMPs (β-defensines, cathelicidins, hepcidines, histone-derivatives and piscidines) were developed for the treatment of fish. They are highly active and stable with no observed cytotoxicities, making them promising candidates for the treatment of aquaristic and aquaculture related diseases.
As part of a global consortium, Numaferm is the manufacturing organization of an anti-Corona nanobody. Extracted from alpacas and developed by Dr. Fernandez and his team in Chile, the nanobody is highly effective in binding to the spike protein and under preclinical evaluation.
For the “lazy” readers amongst us, a great chance to learn more about pepteins, how they are produced at Numaferm and how we help our […]
Read moreNumaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for […]
Read moreOur CEO, Dr. Christian Schwarz and our Business Development Manager, Liv Kaser are looking forward to attend the BIO International Convention in Boston, taking place […]
Read more
CEO and Co-Founder Numaferm GmbH
“We believe that in the near future peptides, pepteins and proteins will have found their way into new markets and become a well-known feedstock for better products in life sciences and beyond. Numaferm supports you in these developments – from discovery to commercial production.”
